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a new avian-origin influenza virus emerged near shanghai in February 2013, and by the beginning of May it had 
caused over 130 human infections and 36 deaths. Human-to-human transmission of avian-origin H7N9 influenza 
a has been limited to a few family clusters, but the high mortality rate (27%) associated with human infection has 
raised concern about the potential for this virus to become a significant human pathogen. european, american, 
and asian vaccine companies have already initiated the process of cloning H7 antigens such as hemagglutinin 
(Ha) into standardized vaccine production vehicles. Unfortunately, previous H7 Ha-containing vaccines have been 
poorly immunogenic. We used well-established immunoinformatics tools to analyze the H7N9 protein sequences 
and compare their T cell epitope content to other circulating influenza a strains as a means of estimating the 
immunogenic potential of the new influenza antigen. We found that the Ha proteins derived from closely related 
human-derived H7N9 strains contain fewer T cell epitopes than other recently circulating strains of influenza, and 
that conservation of T cell epitopes with other strains of influenza was very limited. Here, we provide a detailed 
accounting of the type and location of T cell epitopes contained in H7N9 and their conservation in other H7 and 
circulating (a/california/07/2009, a/Victoria/361/2011, and a/Texas/50/2012) influenza a strains. Based on this analy-
sis, avian-origin H7N9 2013 appears to be a “stealth” virus, capable of evading human cellular and humoral immune 
response. should H7N9 develop pandemic potential, this analysis predicts that novel strategies for improving vac-
cine immunogenicity for this unique low-immunogenicity strain of avian-origin influenza will be urgently needed.
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Introduction
Between February and May 2013, avian-origin H7N9 emerged 
as a significant cause of human morbidity and mortality in 
China, with pandemic potential. As of May 2013, the new influ-
enza virus has caused more than 130 infected patients in China 
to seek hospital care, of which 27% have died and many remain 
hospitalized.1,2 Infections are sporadic, usually associated with 
exposure to birds such as chickens and pigeons, and the extent of 
human-to-human transmission appears to be very low at present. 
Sampling methods may not be entirely accurate since viral titers 
are low in upper respiratory samples, thus some cases of asymp-
tomatic infection and transmission may have been missed.3
Despite the fact that human-to-human transmission seems 
to be rare, the ongoing outbreak of H7N9 influenza is of great 
concern to infectious disease experts for four important reasons. 
First, individual cases of nearly identical H7N9 virus infections 
have been identified in a wide range of locations within China 
in a very short period of time, which strongly suggests that the 
virus is already widespread in an as-yet-unidentified reservoir 
population.4 Second, an H7 subtype influenza has never before 
infected humans to any extent, meaning the human population 
has little or no immunity, which could lead to a very high mortal-
ity rate.5 H7N9 infection has led to death in approximately 27% 
of reported cases, and many infected patients are still hospitalized 
in serious condition.2 Third, viral sequences suggest the possibil-
ity of resistance to certain antiviral medications, rendering some 
current treatments ineffective.1,6 And fourth, viral isolates bear 
hemagglutinin receptor binding site mutations that better enable 
this avian virus to infect mammals, and only a few additional 
mutations might be needed for full adaptation for human-to-
human transmission.6
The source of the viral infections appears to be contact with 
poultry in the majority of cases. Despite these reports, approxi-
mately 40% of patients have had no contact with birds of any 
type.7 Furthermore, the number of infections among chickens in 
market-based samples is very low, an observation that has puzzled 
epidemiologists. Despite these reports of low infection rates, the 
genomic sequences of the virus suggests that the H7N9 sequence 
is closest to poultry-origin H7 viruses,3 and as a result of this 
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association, a mass culling of the poultry population has been 
implemented in Shanghai, Nanjing, and other regions across 
China.33
Alarmingly, human H7N9 cases have already spread 
outside of China; a business man who had traveled to one of 
the affected provinces was recently hospitalized in Taiwan and 
remains in serious condition as of May.8 According to experts 
cited by Nature, 70% of the global population outside of China 
lives within two hours of an airport linked to the outbreak 
regions by either a direct flight or a single connection (Fig. 1).9 
Consequently, should genetic changes occur that permit facile 
human-to-human transmission, the H7N9 outbreak will rapidly 
become a global pandemic.
Analysis of H1N1 (2009) demonstrated cross-conservation 
of T cell epitopes. The current H7N9 outbreak is somewhat 
reminiscent of March 2009, when pandemic H1N1 (A/
California/07/2009) emerged in Mexico. At that time, CDC 
studies showed that most individuals lacked pre-existing humoral 
immunity that was cross-protective against the pandemic 
strain (A/California/07/2009), and that vaccination with the 
2008/2009 seasonal trivalent influenza vaccine (TIV) containing 
H1N1 A/Brisbane/59/2007 rarely elicited neutralizing antibody 
responses against 2009 H1N1 isolates.10,11 Despite this concern, 
during the course of the 2009 pandemic, the new H1N1 was 
not associated with significant morbidity or mortality among 
older adults, a population normally at high risk for complications 
following seasonal influenza infection.12,13
At that time, the importance of T cell epitope responses to 
cross-protective immunity (against different strains of influ-
enza) was already well established. Accordingly, we proposed 
that cross-reactive T memory responses with prior H1N1 viruses 
might protect against severe H1N1 disease, despite the absence 
of cross-reactive humoral immunity, and we published T cell 
epitopes in the hemagglutinin (HA) and neuraminidase (NA) 
proteins that were predicted by immunoinformatic analysis to be 
cross-conserved with HA and NA sequences present in the tri-
valent inactivated influenza vaccine administered that season.14 
This hypothesis was later validated in animal and human studies, 
and the impact of the H1N1 pandemic was, in fact, much less 
severe than had been expected. The lack of B cell epitope cross-
reactivity did not appear to lead to high morbidity and mortality 
rates during the pandemic.
Unfortunately, our prediction is very different for H7N9: we 
find (1) very low T cell epitope content in the HA sequences, 
and (2) very poor potential for cross-reactivity with T cells 
specific for currently circulating influenza strains. Coupled with 
the absence of any prior exposure to H7 in human populations 
(meaning established humoral immunity may be entirely absent), 
these findings suggest that the H7N9 influenza virus, should it 
acquire the ability to be transmitted from person to person, has 
the potential to have a much more serious impact on human 
populations than did pandemic H1N1 influenza in 2009.
Application of in silico analysis to H7N9 demonstrates low 
T cell epitope content. Employing the EpiMatrix immunoin-
formatics suite, we compared the protein sequences of emerging 
H7N9 strains to the sequences of other recent strains of influenza 
and previous H7 strains. We also provide a detailed analysis of 
the T cell epitopes (both class I cytotoxic T cell epitopes and class 
II T helper epitopes) in the H7N9 strains. We find: (1) HA from 
the 2013 outbreak H7N9 and a wide range of avian H7 strains 
have low immunogenic potential (based on T cell epitope anal-
ysis, as previously published)15 when compared with HA from 
Figure 1. The rapid emergence of H7N9 in several locations in china reflects wide-spread distribution in the animal population and potential for even 
greater spread. H7N9 is a virus that deserves serious consideration. should a traveler get infected in china, flight routes from the outbreak regions would 
quickly carry any human-transmissible virus to huge population centers in europe, North america and asia. an estimated 70% of the world popula-
tion resides within two hours’ travel time of destination airports (calculated using gridded population-density maps and a data set of global travel 
times, map supplied by a. J. Tatem, Z. Huang and s. I. Hay (2013). Unpublished data. (a.J.T., University of southampton, UK; Z.H., University of Florida, 
Gainesville; s.I.H., University of Oxford, UK.) Reprinted by permission from Macmillan Publishers Ltd: Nature News 2013.9 
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seasonal influenza strains that are known to be immunogenic; 
(2) H7-HA conservation analysis suggests limited potential for 
T cell epitope cross reactivity with previously and currently cir-
culating seasonal strains; and (3) T cell epitopes that have cross-
reactive potential are found among internal proteins. A full T 
cell epitope analysis for novel avian H7N9 and a list of cross-
conserved epitopes is compiled in this report. This prediction of 
low immunogenic potential and poor epitope conservation has 
important implications for the development of effective H7N9 
vaccines.
Results
Overall HLA class II epitope content. The immunogenic-
ity potential score of H7N9 antigens was derived by summing 
EpiMatrix scores over the entire protein and normalizing for 
protein length. Immunogenicity potential has been directly 
correlated with antibody titers in several published studies.16,18 
The immunogenicity score for H7N9 HA is remarkably low 
(Fig. 2): H7-HA scores -8.11, well below the expectation for a 
random sequence, and also significantly below the scores of 
H1-HA (+18.22) and H3-HA (+14.30). The current H7 also 
scores within the same range as other H7-HA strains, some of 
which were part of poorly immunogenic monovalent inactivated 
vaccines.19,20 Other low-immunogenicity proteins 
that score in the negative range on this immuno-
genicity scale include albumin, transferrin, and the 
immunoglobulin G Fc domain, observations that 
have been previously published by our group.21
HLA class II cluster analysis. We have pub-
lished our approach to finding highly immuno-
genic epitopes that are ‘promiscuous’ and highly 
conserved in multiple strains of the same patho-
gen.22 We call this approach the ‘immunogenic 
consensus sequence (ICS) approach.’ In our own 
work, we have found that these clustered epitopes 
are the most effective ones to include in vaccines to 
promote antibody response and vaccine efficacy.23 
Accordingly, we derived a total of 101 ICS epitopes 
for H7N9, containing multiple 9-mer frames pre-
dicted to bind to many HLA alleles and conserved 
in a minimum of three of the four human-derived 
avian-origin H7N9 sequences (Table 1). ICS were 
derived from among all 11 H7N9 antigens. Of the 
101 ICS class II epitopes, 16 were found to contain 
9-mer sequences that were previously published as 
T cell epitopes or class II MHC binders. None of 
these 16 published 9-mers have been identified in 
the H7N9 influenza surface HA and NA antigens, 
but rather all are found in internal proteins: six in 
M1, eight in NP, and two in PB1 (see ‘Published in 
IEDB’ column, Table 1). 
Next we checked for conservation among cir-
culating strains of influenza and vaccine backbone 
proteins. In this case, we considered all epitopes 
sharing at least 80% amino acid similarity as 
defined by Kesmir  et al. “conserved”.34 Only 11 promiscuous T 
cell epitopes were found in H7N9-HA, and only four of these are 
somewhat cross-conserved in other strains. In contrast, we found 
16 promiscuous helper T cell epitopes in the 2009 H1N1-HA 
sequence, of which nine (56%) were 100% conserved in the 
2008–2009 influenza vaccine strain; 81% were either identical or 
had one conservative amino acid substitution. Thus the emerg-
ing H7N9 is predicted to be less immunogenic, based on our 
analysis, and is also shown to be less conserved in other influenza 
strains. Table S1 provides detailed information on the H7N9 
class II clustered (promiscuous) epitopes, their conservation in 
other influenza strains, and information on published epitopes if 
cross conservation is present.
Cross reactivity—class II. As shown in Table 1, a total of 
96 of the 101 putative epitopes are conserved in other H7N9 
strains. Of the 11 putative H7-HA epitopes, only four have 
minimal cross-reactivity to the current 2012–2013 TIV; three 
are found in A/Victoria/361/2011 (H3N2), one was found in 
A/California/7/2009 (H1N1), and no conserved sequences 
were identified in B/Wisconsin/1/2010. Greater homology 
with H3-HA is expected, as H7 and H3 are group 2 influenza 
A viruses whereas H1 is a group 1 virus. Similarly, only one of 
the six N9-NA putative epitopes was found to be conserved in 
the current TIV, with 86% similarity to the 2012–2013 vaccine 
Figure 2. Potential immunogenicity of emerging influenza a (H7N9) Ha and Ha from 
the current seasonal vaccine and H7 vaccines. The number of HLa ligands (putative T 
cell epitopes) per unit protein is plotted on an Immunogenicity scale. This scale is cor-
related with observed immunogenicity in retrospective and prospective studies.16,17 The 
numbers used in this scale reflect the difference between the number of predicted T cell 
epitopes we would expect to find in a protein of any given size by chance alone (based 
on an evaluation of more than 10,000 random protein sequences) and the number of 
putative epitopes predicted by the epiMatrix system for a given protein. The epiMatrix 
Protein score of an “average” protein is zero. epiMatrix Protein scores above zero indi-
cate the presence of excess MHc ligands and denote a higher potential for immuno-
genicity, while scores below zero indicate the presence of fewer potential HLa ligands 
than expected and a lower potential for immunogenicity. H7 has fewer HLa ligands than 
expected, which is reflected in its negative immunogenicity score. seasonal strains of 
influenza are scored for potential immunogenicity on the left; their scores are much 
higher than H7N9.
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strain A/Victoria/361/2011 (H3N2) as well as the 2013–2014 
vaccine recommendation A/Texas/50/2012 (H3N2). Conversely, 
83 of the 84 putative epitopes derived from internal H7N9 pro-
teins are conserved in at least one of the currently circulating 
influenza A strains. Fourteen H7N9 ICS derived from internal 
proteins are conserved in influenza B/Wisconsin/1/2010; high 
conservation of internal antigen epitopes is consistent in vaccine 
backbone strains. Still, previously circulating strains of influenza 
had more T cell epitopes than were found in the current H7N9.
Epitope content—class I. As shown in Table 2, a total 
of 1,242 putative class I epitopes were found by EpiMatrix, 
spanning the 11 H7N9 antigens across the six supertype class I 
alleles. Of those 1,242 sequences, a total of 48 were found to be 
identified as either published T cell epitopes or MHC binders. 
None of these 48 included epitopes from the external HA and 
NA antigens; instead, the epitopes conserved with published 
epitopes were found in the M1 (17), NP (9), NS1 (1), PA (6), 
and PB1 (15) proteins, as shown in Table 2. Table S2 provides 
detailed information on the H7N9 epitopes, their conservation 
in other influenza strains, and information on published epitopes 
if cross-conservation is present.
Cross reactivity—class I. A total of 967 (77.9%) of the 
1,242 putative epitopes were found to be > 90% conserved in 
other H7N9 strains. Only 4/150 and 1/146 HA and NA class 
I putative epitopes, respectively, were found to be conserved in 
the current 2012–2013 TIV, which is not surprising since this 
is an entirely new strain of influenza for the human population. 
A similar trend of low conservation can be seen when H7N9 is 
compared with the LAIV backbone strain and the strains recom-
mended for 2013–2014 vaccination. A total of 609 of the remain-
ing 946 putative class I epitopes, spanning the internal proteins, 
were found to be conserved in one or more of the circulating 
2012–2013 influenza A strains. Similar conservation trends can 
be seen when comparing the epitopes derived from internal anti-
gens to the LAIV backbone strain and the strains recommended 
for 2013–2014 vaccination.
The above analysis is based on in silico predictions using a 
well-validated immunoinformatics toolkit.24 Based on historical 
performance, we expect these epitope predictions to be 93-99% 
accurate; in addition, correlations with published H1N1 and 
H3N2 epitopes are provided in Tables S1 and S2. Our findings 
suggest that overall H7-HA immunogenicity will be poor, and 
that immune responses to H7N9 will be driven by T cell epitopes 
found in the internal proteins. Given the poor immunogenicity of 
previous H7 vaccines,25 whole attenuated or inactivated vaccines 
containing a greater number of T cell epitopes in their internal 
proteins (or subunit vaccines that incorporate conserved internal 
protein T cell epitopes) may be more effective immunogens than 
subunit HA/NA for H7N9.
Discussion
In 2009, we performed a similar analysis of H1N1, follow-
ing emergence of the H1N1 2009 virus. Using EpiMatrix, a 
T cell epitope prediction and comparison tool, we compared 
the sequences of the three HA and NA proteins contained in 
2008–2009 TIV to their counterparts in A/California/04/2009 
(H1N1), looking for cross-conserved T cell epitope sequences. We 
found > 50% conservation of T helper and cytotoxic T lympho-
cyte (CTL) epitopes between novel swine-origin influenza virus 
and TIV HA for selected HLA.14 At that time, we suggested that 
seasonal influenza vaccination or infection might protect against 
Table 1. Numbers of putative class II Ics constructed from the four emerging avian H7N9 strains and numbers of those epitopes conserved (at least 80% 
amino acid similarity) in recently circulating and vaccine backbone influenza strains
H
7N
9 
 
ag
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ta
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ito
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er
 H
7N
9 2012–2013 vaccine strains
2013–2014 vaccine 
recommendations
Vaccine backbone
a/california/ 
7/2009  
(H1N1)
a/Victoria/ 
361/2011 
(H3N2)
a/christchurch/ 
16/2010  
(H1N1)
a/Texas/ 
50/2012  
(H3N2)
TIV LaIV
a/Puerto Rico/ 
8/34 (H1N1)
a/ann arbor/7/67 
(H2N2)
Ha 11 0 10 1 3 2 3  
M1 9 6 9 9 9 9 9 9 9
M2 2 0 2 2 2 2 2 2 2
Na 6 0 5 0 1 0 1  
NeP 6 0 5 6 6 -- 6 6 6
NP 11 8 11 9* 11 -- 11 11 11
Ns1 3 0 2 3 3 -- 3 3 3
Pa 14 0 14 14 14 -- 14 14 14
PB1 18 2 17 18 18 -- 18 18 18
PB1-F2 1 0 1 -- 0 -- 0 1 1
PB2 20 0 20 20 20 -- 20 20 20
counts of published epitopes from IeDB mapped to H7N9 Ics are shown in the third column. Table values marked with ‘--‘ represent an antigen (ag) that 
was unavailable for download. It can be easily seen that peptides from Ha and Na are less conserved among other strains than epitopes derived from the 
internal proteins. *a/california/7/2009 NP sequence accessed from GIsaID was truncated and did not cover c-terminal NP Ics.
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pandemic H1N1. We then extended the analysis to define 
core T cell epitopes in H1N1 2009, and to define the extent 
of cross-reactivity between the pandemic virus and the 2009-
2010 seasonal H1N1 vaccine strain, A/Brisbane/59/2007. The 
2009 H1-HA protein contained 16 class II (T helper) peptide 
sequences that were both highly conserved between the pan-
demic and A/Brisbane/59/2007 H1N1 strains and likely to be 
presented in the context of multiple HLA alleles.14 Schanen et 
al. (VaxDesign), in collaboration with EpiVax, then confirmed 
that human influenza-specific T helper cells from donors not 
previously exposed to H1N1 2009 were capable of generat-
ing cross-reactive effector responses against the 2009 H1N1 
virus.26 These studies helped support the hypothesis that exist-
ing influenza-specific CD4+ T cells generated cross-protective 
cellular responses that limited disease severity and virus spread 
in individuals lacking cross-reactive humoral immunity, and 
was substantiated by subsequent animal studies demonstrating 
that seasonal H1N1 exposure protected ferrets27 and mice (Ted 
Ross, unpublished) from disease in pandemic H1N1 infection.
Our previous study contradicted predictions that H1N1 would 
cause serious illness in human populations. Even though H1N1 
spread rapidly (presumably due to the absence of any memory B 
cell response), hospitalizations were limited to younger individu-
als and pregnant women who might have had limited prior expo-
sure to influenza and absent T memory responses.
The lack of antibody response to the 2009 H1N1 is similar 
to the situation with the current H7N9, but from the T cell per-
spective, the two are markedly different. If H7N9 becomes easily 
transmissible between humans, widespread transmission (due to 
the absence of memory B cell responses and antibody that might 
protect against H7, which has never circulated in human popula-
tions) and widespread illness (due to the absence of cross-reac-
tive T cell potential) are probable. The mortality rate following 
establishment of H7N9 disease is greater than 27%; thus concern 
about the potential for this virus to cause significant morbidity 
and mortality in human populations, should the virus adapt to 
spread from human to human, are entirely justified.
In addition, due to the poor predicted immunogenicity of 
H7N9, inactivated vaccines based on the H7-HA and N9-NA 
antigens, whether produced in eggs or mammalian cells, are 
likely to be poorly immunogenic based on the analysis described 
here. Previous studies of influenza vaccines have clearly demon-
strated the link between T cell response and antibody titers,28 
thus the absence of T helper epitopes in the HA antigen of the 
current circulating strain of H7N9 can be expected to lead to 
very poor immunogenicity, particularly for subunit vaccines 
containing HA alone. New strategies that will improve protec-
tion against H7N9 are needed, as the virus has the potential to 
become a worldwide threat.
Alternative vaccine approaches for H7N9 would include: (1) 
addition of adjuvants to boost immune responses against the 
weaker T cell epitopes; (2) addition of cross-conserved epitopes 
to the HA in a subunit vaccine (as proposed by our team to 
NIAID); (3) enhancement of the HA with cross-conserved epit-
opes (a vaccine design currently under production at EpiVax); (4) 
development of T cell vaccines for influenza that contain all of 
the most immunogenic T cell epitopes derived from H7, includ-
ing those that are cross conserved with H7N9 (a DNA-string-of 
beads design is currently in production); and (5) use of two doses 
of vaccine rather than one.
Table 2. Numbers of putative class I epitopes discovered in four emerging avian H7N9 strains and numbers of those epitopes conserved (at least 80% 
amino acid similarity) in recently circulating and vaccine backbone influenza strains
H
7N
9 
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7N
9
2012/2013 vaccine strains
2013/2014 vaccine 
recommendations
Vaccine backbone
A/California/ 
7/2009 (H1N1)
A/Victoria/ 
361/2011 (H3N2)
A/Christchurch/ 
16/2010 (H1N1)
A/Texas/ 
50/2012 
(H3N2)
TIV LAIV
A/Puerto Rico/ 
8/34 (H1N1)
A/Ann Arbor/7/67 
(H2N2)
Ha 150 0 122 2 2 2 2
M1 89 17 52 55 45 55 45 53 45
M2 53 0 38 26 22 26 22 21 19
Na 146 0 130 1 1 1 1
NeP 53 1 45 12 20 – 20 26 30
NP 146 8 126 59* 59 – 60 77 67
Ns1 91 1 32 18 15 – 15 27 21
Pa 150 6 130 115 103 – 104 118 109
PB1 150 15 137 111 115 – 115 111 123
PB1-F2 64 0 15 – 0 – 0 3 4
PB2 150 0 140 123 90 – 90 103 110
counts of published epitopes from IeDB mapped to H7N9 epitopes discovered here are shown in the third column. Table values marked with ‘–‘ represent 
an antigen (ag) that was unavailable for download. epitope sequences from Ha and Na are less conserved among other strains than epitopes derived from 
the internal proteins. *a/california/7/2009 NP sequence accessed from GIsaID was truncated and did not cover c-terminal NP Ics.
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In contrast with 2009 H1N1, 2013 H7N9 is a significant 
concern for global health. As described above, H7N9 has 
fewer epitopes than would normally occur in a random protein 
sequence. As this virus has not, by current reports, circulated in 
humans previously, it is unclear why the virus would evolve to 
have fewer T cell epitopes than predicted. Those T cell epitopes 
that we predict might be of use for vaccine design are included 
in the supplemental tables (Tables S1 and S2) as a service to the 
influenza vaccine development community. Whether ‘evolution-
ary’ in nature or not, we postulate that the relative paucity of 
T cell epitopes (both novel and conserved) in the key antigens 
of emerging H7N9 will have serious consequences for human 
immune response and vaccine design.
Materials and Methods
Sequence collection. Four human H7N9 influenza sequences 
were downloaded from GISAID (http://platform.gisaid.org/). 
The downloaded sequences were from A/Hangzhou/1/2013, A/
Anhui/1/2013, A/Shanghai/1/2013, and A/Shanghai/2/2013. 
The 25 remaining non-human H7N9 strains available on 
GISAID were also downloaded to confirm if epitopes found 
within the four human-sourced strains were conserved in H7N9 
as a whole, which would indicate functional dependency and low 
probability of mutation. The novel H7N9 sequences analyzed 
were selected from sequences that were available on GISAID 
on April 6th, 2013. Three additional influenza strains found in 
the current 2012–2013 TIV [A/California/07/2009(H1N1), A/
Victoria/361/2011(H3N2), and B/Wisconsin/01/2010] were also 
downloaded for evaluation of conservation and cross-protection 
with EpiMatrix-identified H7N9 T cell epitopes.
The following accessions were utilized for epitope cross-
conservation analysis: A/California/7/2009 (H1N1): GISAID 
EPI_ISL_77637; A/Victoria/361/2011 (H3N2): GISAID EPI_
ISL_134450;  B/Wisconsin/01/2010: GISAID EPI_ISL_115174; 
A/Christchurch/16/2010 (H1N1): GISAID EPI_ISL_79722; 
A/Texas/50/2012 (H3N2): GISAID EPI_ISL_136503; A/Ann 
Arbor/7/1967 (H2N2): GISAID EPI_ISL_130404; A/Puerto 
Rico/8/34 (H1N1): Genbank AAM75164.1; AAM75162.1; 
AAM75610.1; AAM75158.1; AAM75156.1; AAM75163.1; 
AAM75161.1; AAM75159.1; AAM75157.1; AAM75155.1; 
ADX99593.1.
Conservatrix. The Conservatrix algorithm29 was employed to 
parse and compare 9-mers and 10-mers (class I analysis only) for 
highly conserved segments among the four human H7N9 influ-
enza sequences, organized by protein of origin: HA, M1, M2, 
NA, NEP, NP, NS1, PA, PB1, PB1-F2, or PB2. Highly conserved 
epitope sequences were then analyzed for putative binding to eight 
common HLA class II (DRB1*0101, DRB1*0301, DRB1*0401, 
DRB1*0701, DRB1*0801, DRB1*1101, DRB1*1301, 
DRB1*1501) and six common HLA class I alleles (A0101, A0201, 
A0301, A2402, B0702, and B4403).
EpiMatrix. Using the EpiMatrix algorithm,30 epitopes were 
selected from the output of highly conserved epitopes produced 
by Conservatrix. Each amino acid was scored for predicted 
affinity to eight common HLA class II and six common HLA 
class I alleles, covering > 90% of the human population.31
EpiAssembler. Sets of overlapping, conserved, and 
immunogenic class II epitopes were identified and assembled 
into extended immunogenic consensus sequences (ICS) with 
the EpiAssembler32 tool. Processing and presentation of these 
sequences would allow for presentation of the highly conserved 
peptides in the context of more than one class II MHC. The 
resulting peptide is not a “pseudo-sequence” as such, since each 
constituent epitope occurs in its corresponding position in the 
native protein but in different variants of the pathogen. These 
epitopes are of high value for vaccine design as they are both 
promiscuous and highly conserved.
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